Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BP 2201

Next Previous
X
Search
Drug Profile

BP 2201

Alternative Names: BP-2201; iPS-NKT - BrightPath Biotherapeutics

Latest Information Update: 10 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RIKEN
  • Developer BrightPath Biotherapeutics; RIKEN
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Head and neck cancer

Most Recent Events

  • 10 Aug 2023 BP 2201 is still in phase I trials for Head and neck cancer in Japan (Parenteral) (BrightPath Biotherapeutics pipeline, August 2023)
  • 02 May 2023 BrightPath enters into licensing agreement with Artisan for STAR-CRISPR editing platform to accelerate development of iPSC derived cell therapy platform
  • 05 Oct 2021 BP 2201 is available for licensing as of 05 Oct 2021. https://www.brightpathbio.com
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top